Quality of Life and Self-esteem After Botox® Injections in Depressed and Non-depressed Patients

Inclusion Criteria: 1. Female subjects,aged between 25 to 60 years; 2. Subjects diagnosed as having major depression according to the criteria of DSM-IV, MINI International Neuropsychiatric Interview (MINI Brazilian version 5.0.0); 3. Subjects who are being administered a therapeutic dose of an approved, prescribed antidepressant medication (pattern doses of the literature), and have been using mentioned medication at a stable therapeutic dose for at least three months prior to the randomization visit; 4. Subjects with mild (1), moderate (2) or severe (3) glabellar frown lines while at rest according the Severity Wrinkles Scales; 5. Female subjects of childbearing age that present a negative urine pregnancy test and are using an effective contraceptive method; 6. Subjects who had never received botulinum toxin A previously; 7. Subjects agreeing to take part of the study, after being fully informed of the purpose and the nature of the investigation and after having signed the informed consent form; 8. Subjects who will be available throughout the duration of the study; 9. Subjects with sufficient schooling and awareness to enable them to cooperate to the degree required by this protocol; 10. Subjects with Critical appreciation preserved, attested by their assistant psychiatrist (for group1); 11. Subjects who reside with other family members who assume co-responsibility in the study. Exclusion Criteria: 1. Subjects whose medical history and physical examination present clinical pathology, as myasthenia gravis, Eaton-Lambert Syndrome, neoplasm, muscular diseases, motor neuron diseases, systemic autoimmune or neurological diseases; 2. Pregnant or women in breastfeeding, or women planning to become pregnant 3. Subjects with suicide risk; 4. Subjects addicted to alcohol or illegal drugs within the last 6 months; 5. Subjects using amino glycoside and penicillamine antibiotics, quinine and Ca2+ channel blockers; 6. Subjects using medications that, in the opinion of the investigator may cause depression, such as beta-blockers, oral corticosteroids and interferon; 7. Subjects who, in the opinion of the investigator, may potentially require psychiatric hospitalization during the course of the study; 8. Subjects with inflammation or active infection in the area to be injected; 9. Subjects with a history of non-adherence to medical treatment, or who demonstrate unwillingness to adhere to the study protocol; 10. The presence of any additional active DSM-IV Axis I diagnosis, or mental retardation; 11. History of psychiatric hospitalization within the past three years.